Olmesartan medoxomil treatment potently improves cardiac myosin-induced dilated cardiomyopathy via the modulation of ACE-2 and ANG 17 mas receptor

Free Radical Research

Volumn 46, Issue 7, 2012, Pages 850-860

  Sukumaran, Vijayakumar ^a   Veeraveedu, Punniyakoti T ^a,b   Lakshmanan, Arun Prasath ^a   Gurusamy, Narasimman ^c   Yamaguchi, Ken'Ichi ^d   Ma, Meilei ^a   Suzuki, Kenji ^d   Kodama, Makoto ^d   Watanabe, Kenichi ^a  

^a NIIGATA UNIVERSITY OF PHARMACY AND APPLIED LIFE SCIENCES   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

Author keywords

Angiotensin 1 7; Angiotensin converting enzyme 2; Dilated cardiomyopathy; Inflammation; Olmesartan medoxomil; Oxidative stress

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; CARDIAC MYOSIN; GELATINASE A; MESSENGER RNA; OLMESARTAN; PROTEIN P67; SUPEROXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; FIBROSIS; HYPERTROPHY; IMMUNIZATION; LEWIS RAT; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; UPREGULATION;

ANGIOTENSIN I; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BIOLOGICAL MARKERS; CARDIAC MYOSINS; CARDIOMYOPATHY, DILATED; ENDOPEPTIDASES; FIBROSIS; GENE EXPRESSION REGULATION; HEART; HYPERTROPHY, LEFT VENTRICULAR; IMIDAZOLES; MITOGEN-ACTIVATED PROTEIN KINASES; PEPTIDE FRAGMENTS; PEPTIDYL-DIPEPTIDASE A; PROTO-ONCOGENE PROTEINS; RATS; RECEPTORS, G-PROTEIN-COUPLED; RNA, MESSENGER; TETRAZOLES;

EID: 84862175607     PISSN: 10715762     EISSN: 10292470     Source Type: Journal    
DOI: 10.3109/10715762.2012.684878     Document Type: Article

References (38)

1. Kodama M, Matsumoto Y, Fujiwara M, Masani F, Izumi T, Shibata A. A novel experimental model of giant cell myocarditis induced in rats by immunization with cardiac myosin fraction. Clin Immunol Immunopathol 1990;57:250-262.
2. Kodama M, Zhang S, Hanawa H, Shibata A. Immunohisto-chemical characterization of infi ltrating mononuclear cells in the rat heart with experimental autoimmune giant cell myocarditis. Clin Exp Immunol 1992;90:330-335.
3. Kodama M, Hanawa H, Saeki M, Hosono H, Inomata T, Suzuki K, Shibata A. Rat dilated cardiomyopathy after autoimmune giant cell myocarditis. Circ Res 1994;75:278-284.
4. Santos RA, Ferreira AJ, Simoes ESAC. Recent advances in the angiotensin-converting enzyme2-angiotensin (1-7)-mas axis. Exp Physiol 2008;93:519-527.
5. Igase M, Strawn WB, Gallagher PE, Geary RL, Ferrario CM. Angiotensin II AT1 receptors regulate ACE2 and angiotensin-(1-7) expression in the aorta of spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 2005;289:H1013-H1019.
6. Kassiri Z, Zhong J, Guo D, Basu R, Wang X, Liu PP, et al. Loss of angiotensin-converting enzyme 2 accelerates maladap-tive left ventricular remodeling in response to myocardial infarction. Circ Heart Fail 2009;2:446-455.
7. Tallant EA, Clark MA. Molecular mechanisms of inhibition of vascular growth by angiotensin-(1-7). Hypertension 2007;42: 574-579.
8. Ferrario CM, Chappell MC, Tallant EA, Brosnihan KB, Diz D. Counterregulatory actions of angiotensin-(1-7). Hypertension 1997;30:535-541.
9. Roks AJ, van Geel PP, Pinto YM, Buikema H, Henning RH, de Zeeuw D, van Gilst WH. Angiotensin-(1-7) is a modulator of the human renin-angiotensin system. Hypertension 1999;4: 296-301.
10. Zhong JC, Huang DY, Yang YM, Li YF, Liu GF, Song XH, Du K. Upregulation of angiotensin-converting enzyme 2 by all-trans retinoic acid in spontaneously hypertensive rats. Hypertension 2004;44:907-912.
11. Zhao YX, Yin HQ, Yu QT, Qiao Y, Dai HY, Zhang MX, et al. ACE-2 overexpression ameliorates left ventricular remodeling and dysfunction in a rat model of myocardial infarction. Hum Gene Ther 2010;21:1545-1554.
12. Tallant EA, Ferrario CM, Gallagher PE. Cardioprotective role for angiotensin-(1-7) and angiotensin converting enzyme 2 in the heart. Future Cardiol 2006;2:335-342.
13. Trask AJ, Ferrario CM. Angiotensin-(1-7): pharmacology and new perspectives in cardiovascular treatments. Cardiovasc Drug Rev 2007;25:162-174.
14. Grobe JL, Mecca AP, Lingis M, Shenoy V, Bolton TA, Mach-ado JM, et al. Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1-7). Am J Physiol Heart Circ Physiol 2007;292:H736-H742.
15. Kaiqiang Ji, Minakawa M, Fukui K, Suzuki Y, Fukuda I. Olmesartan improves left ventricular function in pressure-overload hypertrophied rat heart by blocking angiotensin II receptor with synergic eff ects of upregulation of angiotensin converting enzyme 2. Ther Adv Cardiovasc Dis 2009;3: 103-111.
16. Ishiyama Y, Gallagher PE, Averill DB, Tallant EA, Brosnihan KB, Ferrario CM. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension 2004;43:970-976.
17. Sukumaran V, Veeraveedu PT, Gurusamy N, Lakshmanan AP, Yamaguchi K, Ma M, et al. Olmesartan attenuates the development of heart failure after experimental autoimmune myocarditis in rats through the modulation of ANG 1-7 mas receptor. Mol Cell Endocrinol 2012;351:208-219.
18. Sukumaran V, Watanabe K, Veeraveedu PT, Thandavarayan RA, Gurusamy N, Ma M, et al. Benefi cial eff ects of olme-sartan, an angiotensin II receptor type 1 antagonist, in rats with dilated cardiomyopathy. Exp Biol Med (Maywood) 2010;235: 1338-1346.
19. Sukumaran V, Watanabe K, Veeraveedu PT, Gurusamy N, Ma M, Thandavarayan RA, et al. Olmesartan, an AT 1 antagonist, attenuates oxidative stress, endoplasmic reticulum stress and cardiac infl ammatory mediators in rats with heart failure induced by experimental autoimmune myocarditis. Int J Biol Sci 2011;7:154-167.
20. Takaya T, Kawashima S, Shinohara M, Yamashita T, Toh R, Sasaki N, et al. Angiotensin II type 1 receptor blocker telmisartan suppresses superoxide production and reduces atherosclerotic lesion formation in apolipoprotein E-defi cient mice. Atherosclerosis 2006;186:402-410.
21. Watanabe E, Matsuda N, Shiga T, Kajimoto K, Ajiro Y, Kawarai H, et al. Signifi cance of 8-hydroxy-2 ′-deoxyguanosine levels in patients with idiopathic dilated cardiomyopathy. J Card Fail 2006;12:527-532.
22. Ashizawa N, Graf K, Do YS, Nunohiro T, Giachelli CM, Meehan WP, et al. Osteopontin is produced by rat cardiac fi broblasts and mediates A (II)-induced DNA synthesis and collagen gel contraction. J Clin Invest 1996;98:2218-2227.
23. See F, Thomas W, Way K, Tzanidis A, Kompa A, Lewis D, et al. p38 mitogenactivated protein kinase inhibition improves cardiac function and attenuates left ventricular remodeling following myocardial infarction in the rat. J Am Coll Cardiol 2004;44:1679-1689.
24. Liang Q, Elson AC, Gerdes AM. p38 MAP kinase activity is correlated with angiotensin II type 1 receptor blocker-induced left ventricular reverse remodeling in spontaneously hypertensive heart failure rats. J Card Fail 2006;12:479-486.
25. Machado RD, Santos RA, Andrade SP. Mechanisms of angiotensin-(1-7)- induced inhibition of angiogenesis. Am J Physiol Regul Integr Comp Physiol 2001;280:R994-R1000.
26. da Silveira KD, Coelho FM, Vieira AT, Sachs D, Barroso LC, Costa VV, et al. Anti-infl ammatory eff ects of the activation of the angiotensin-(1-7) receptor, MAS, in experimental models of arthritis. J Immunol 2010;185:5569-5576.
27. Liu CX, Hu Q, Wang Y, Zhang W, Ma ZY, Feng JB, et al. Angiotensin-converting enzyme 2 overexpression remarkably ameliorated glomerular injury in a rat model of diabetic nephropathy: A comparison with ACE inhibition. Mol Med 2010;17:59-69.
28. Bodiga S, Zhong JC, Wang W, Basu R, Lo J, Liu GC, et al. Enhanced susceptibility to biomechanical stress in ACE2 null mice is prevented by loss of the p47 (phox) NADPH oxidase subunit. Cardiovasc Res 2011;91:151-161.
29. Maejima Y, Okada H, Haraguchi G, Onai Y, Kosuge H, Suzuki JI, Isobe M. Telmisartan, a unique ARB, improves left ventricular remodeling of infarcted heart by activating PPAR gamma. Lab Invest 2011;91:932-944.
30. Lakshmanan AP, Watanabe K, Thandavarayan RA, Sari FR, Harima M, Giridharan VV, et al. Telmisartan attenuates oxida-tive stress and renal fi brosis in streptozotocin induced diabetic mice with the alteration of angiotensin-(1-7) mas receptor expression associated with its PPAR-g agonist action. Free Radic Res 2011;45:575-584.
31. Mercure C, Yogi A, Callera GE, Aranha AB, Bader M, Ferreira AJ, Santos RA, Walther T, Touyz RM, Reudelhuber TL. Angi-otensin (1-7) blunts hypertensive cardiac remodeling by a direct eff ect on the heart. Circ Res 2008;103:1319-1326.
32. Iwata M, Cowling RT, Gurantz D, Moore C, Zhang S, Yuan JX, Greenberg BH. Angiotensin-(1-7) binds to specifi c receptors on cardiac fi broblasts to initiate antifi brotic and ant-itrophic eff ects. Am J Physiol Heart Circ Physiol 2005;289: H2356-H2363.
33. Pan CH, Wen CH, Lin CS. Interplay of angiotensin II and angiotensin (1-7) in the regulation of matrix metalloprotein-ases of human cardiocytes. Exp Physiol 2008;93: 599-612.
34. Pfeff er MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 1990;81:1161-1172.
35. Zhong J, Basu R, Guo D, Chow FL, Byrns S, Schuster M, et al. Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fi brosis, and cardiac dysfunction. Circulation 2010;122:717-728.
36. Zhong JC, Ye JY, Jin HY, Yu X, Yu HM, Zhu DL, et al. Tel-misartan attenuates aortic hypertrophy in hypertensive rats by the modulation of ACE2 and profi lin-1 expression. Regul Pept 2011;166:90-97.
37. Koka V, Huang XR, Chung AC, Wang W, Truong LD, Lan HY. Angiotensin II up-regulates angiotensin I-converting enzyme (ACE), but down-regulates ACE2 via the AT1-ERK/p38 MAP kinase pathway. Am J Pathol 2008, 172, 1174-1183.
38. Tallant EA, Ferrario CM, Gallagher PE. Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor. Am J Physiol Heart Circ Physiol. 2005; 289:H1560-1566.